Αποτελέσματα Αναζήτησης
12 Απρ 2024 · Endoscopic sleeve gastroplasty achieved and sustained greater weight loss compared with semaglutide over a 5-year time horizon for the modeled patients (BMI of 31.7 vs 33.0). Over 1 year, ESG was not cost-effective compared with semaglutide, with an ICER of $240 265/QALY (Table 2).
30 Σεπ 2020 · We found an average TBWL of 15.9% at 5 years after the procedure, with 90% of the patients maintaining a TBWL of 5% or more. Importantly, we were able to show that patients' weight loss evaluated only 1 month after the ESG is an independent predictor of their weight loss throughout the follow-up.
20 Ιουλ 2020 · Peer Review reports. Background. Evidence shows that bariatric surgery is more effective than conventional therapy for the control of obesity and its associated comorbidities [1].
30 Ιαν 2024 · Coprimary end points at 5 years are efficacy (weight loss) (>95% power) and safety (incidence of predefined adverse events) (80% power). In this article, we report perioperative outcome data (0-30 days) and 90-day mortality, using a per-protocol analysis, with participants analyzed according to the procedure they received.
Patients who had gastric bypass (RYGB) had greater weight loss, a slightly higher T2DM remission rate, less T2DM relapse, and better long-term glycemic control compared with those who had sleeve gastrectomy (SG) [1].
2 Απρ 2022 · Weight failure after sleeve gastrectomy (SG) is frequently observed. Consensus on the most effective treatment is lacking. The aim of this meta-analysis was to assess revisional strategies for weight regain (WR) or insufficient weight loss (IWL) following SG.
25 Απρ 2024 · An alternative technique using endoscopy for sleeve gastroplasty has shown to be safe and efficient for weight loss after 104 weeks, with important improvements in metabolic comorbidities 43.
